News Focus
News Focus
icon url

supersteve13

10/10/22 2:08 PM

#520716 RE: SkyLimit2022 #520713

Just saw the NVCR insider sales of late- ouch!
icon url

HyGro

10/10/22 7:00 PM

#520816 RE: SkyLimit2022 #520713

But yet Optune achieved 13% nOS in a Phase 3 trial and has been approved in multiple indications in multiple countries. NWBO's Phase 3 trial resulted in virtually NO share gains whatsoever. Is still very uncertain in gaining any approval after a 16 year trial that burned over a BILLION dollars in shareholder money and has only made the CEO rich.
icon url

Roman516

10/11/22 8:44 AM

#520905 RE: SkyLimit2022 #520713

Well stated with supporting facts.